{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:34:36Z","timestamp":1773516876580,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1093\/rheumatology\/ket487","type":"journal-article","created":{"date-parts":[[2014,2,9]],"date-time":"2014-02-09T01:36:55Z","timestamp":1391909815000},"page":"2167-2174","source":"Crossref","is-referenced-by-count":88,"title":["Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia"],"prefix":"10.1093","volume":"53","author":[{"given":"Roy","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Tain","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Suster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zancong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Polvent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Hingorani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Quart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Manhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey N.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,2,8]]},"reference":[{"key":"key\n\t\t\t\t20170522160551_ket487-B1","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/art.20438","article-title":"Gout: on the brink of novel therapeutic options for an ancient disease","volume":"50","author":"Bieber","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170522160551_ket487-B2"},{"key":"key\n\t\t\t\t20170522160551_ket487-B3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1758-5996-4-12","article-title":"High plasma uric acid concentration: causes and consequences","volume":"4","author":"de Oliveira","year":"2012","journal-title":"Diabetol Metab Syndr"},{"key":"key\n\t\t\t\t20170522160551_ket487-B4","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170522160551_ket487-B5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170522160551_ket487-B6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.24612","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis","volume":"61","author":"Kim","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170522160551_ket487-B7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522160551_ket487-B8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","article-title":"Epidemiology of gout","volume":"12","author":"Roddy","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20170522160551_ket487-B9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehi879","article-title":"Uric acid and inflammatory markers","volume":"27","author":"Ruggiero","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170522160551_ket487-B10","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20170522160551_ket487-B11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522160551_ket487-B12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170522160551_ket487-B13","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/art.23803","article-title":"Treatment-failure gout: a moving target","volume":"58","author":"Edwards","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170522160551_ket487-B14","first-page":"2437","article-title":"The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years","volume":"30","author":"Darmawan","year":"2003","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20170522160551_ket487-B15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170522160551_ket487-B16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1185\/03007995.2011.552570","article-title":"Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings","volume":"27","author":"Pandya","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20170522160551_ket487-B17","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522160551_ket487-B18","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20170522160551_ket487-B19"},{"key":"key\n\t\t\t\t20170522160551_ket487-B20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170522160551_ket487-B21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522160551_ket487-B22","first-page":"320","article-title":"RDEA594: a potent URAT1 inhibitor without affecting other important renal transporters, OAT1 and OAT 3 [abstract]","volume":"68","author":"Yeh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170522160551_ket487-B23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/11592750-000000000-00000","article-title":"The challenges of gout management in the elderly","volume":"28","author":"Stamp","year":"2011","journal-title":"Drugs Aging"},{"key":"key\n\t\t\t\t20170522160551_ket487-B24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20170522160551_ket487-B25","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d?","volume":"22","author":"Jansen","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t20170522160551_ket487-B26","first-page":"702","article-title":"Renal impairment and poor outcomes of allopurinol therapy in US gout patients [abstract]","volume":"60","author":"Pandya","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170522160551_ket487-B27","first-page":"187","article-title":"Lesinurad (RDEA594), a novel investigational uricosuric agent for hyperuricemia and gout, blocks transport of uric acid induced by hydrochlorothiazide [abstract]","volume":"70","author":"Tan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170522160551_ket487-B28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170522160551_ket487-B29","first-page":"412","article-title":"Uric acid stones","volume":"16","author":"Asplin","year":"1996","journal-title":"Semin Nephrol"},{"key":"key\n\t\t\t\t20170522160551_ket487-B30","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1007\/BF00301527","article-title":"Prophylaxis of uric acid and cystine stones","volume":"18","author":"Hess","year":"1990","journal-title":"Urol Res"},{"key":"key\n\t\t\t\t20170522160551_ket487-B31","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/BF01712184","article-title":"Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?","volume":"62","author":"Mertz","year":"1984","journal-title":"Klin Wochenschr"},{"key":"key\n\t\t\t\t20170522160551_ket487-B32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00315283","article-title":"The effect of benzbromarone on allopurinol\/oxypurinol kinetics in patients with gout","volume":"44","author":"Muller","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170522160551_ket487-B33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","article-title":"Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects","volume":"45","author":"Khosravan","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20170522160551_ket487-B34","first-page":"U2808","article-title":"Colchicine prescribing and safety monitoring in patients with gout","volume":"120","author":"Ly","year":"2007","journal-title":"N Z Med J"},{"key":"key\n\t\t\t\t20170522160551_ket487-B35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.taap.2012.06.020","article-title":"Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers","volume":"263","author":"Galtier","year":"2012","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/53\/12\/2167\/17388308\/ket487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T05:01:50Z","timestamp":1503550910000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-lookup\/doi\/10.1093\/rheumatology\/ket487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,8]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,2,8]]},"published-print":{"date-parts":[[2014,12]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/ket487","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2,8]]}}}